Due to its comprehensive effect on all players in the inner ear AC102 is the only breakthrough approach for the treatment of hearing loss and tinnitus and electrode insertion trauma. A Phase II clinical trial for acute hearing loss will start later this year, while clinical studies in chronic hearing loss and tinnitus are to follow. Furthermore, our pipeline neuroregenerative and neuroprotective compounds are in development for Parkinson’s and other neurodegenerative diseases.
Our first indication of acute hearing loss is a life-changing disorder with an untapped market. AC102 has shown outstanding and unmatched efficacy. Safety and tolerabitly in animals and humans is excellent.
AC102 and our pipeline candidates are small molecules and new chemical entities. All our IP is solely owned by AudioCure and protected very-long term by composition-of-matter patents. Pipeline compounds will be filed accordingly soon.